End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
79,600 KRW | +1.02% |
|
+4.46% | +15.70% |
05-16 | Yuhan Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.03 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.70% | 4.28B | B- | ||
+7.91% | 72.21B | A | ||
+14.98% | 9.14B | A- | ||
-23.31% | 4.33B | A- | ||
+32.83% | 4.15B | - | ||
+9.28% | 2.19B | B | ||
-33.37% | 1.98B | C- | ||
+9.30% | 1.98B | - | - | |
-46.20% | 1.68B | - | ||
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A000100 Stock
- Ratings Yuhan Corporation